AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 251 min read$STOK

Stoke Therapeutics, Inc. (STOK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (t

Original reporting
SEC EDGAR 8-K
Published Sep 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$STOK
Neutral
medium confidence
Mentioned
$STOK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STOKNeutralLow
01

Why it matters

The appointment includes a cash retainer and sizable stock option grant, which may be viewed positively by investors seeking stability.

02

Market read

Corporate governance update with modest compensation details; limited immediate trading impact.

03

What to watch

Potential strategic direction shift if new director brings industry connections.

Relevance 6/10Novelty 5/10Timing: effective Sep 23 2026

Background

SEC Form 8‑K filing discloses board changes for Stoke Therapeutics, a biotech listed on Nasdaq.

Company-level read

Ticker impact

$STOKNeutralMedium confidence
Context

SEC 8‑K reports resignation of director Dr. Edward M. Kaye and appointment of Alexander Cumbo with cash retainer and stock option grant.

Expected impact

Potential modest price movement as investors assess new director's impact.

Evidence & confidence

Director resignations are routine but the accompanying $45k retainer and $724k option grant provide material detail that could influence sentiment.

Market effects

Sector

Minor impact on biotech governance outlook.

Regional

U.S. market only.

Global

Limited.

Counterpoint

What could challenge this read

Director change unlikely to move the stock significantly.

Key entities

  • person
    Edward M. Kaye, M.D.

    Resigning Class III director.

  • person
    Alexander (Bo) Cumbo

    Newly appointed Class III director.

Read at source← All news

Related articles

SEP 9
$STOKMedAI 8/10

Stoke Therapeutics at Cantor conference: dravet data, cash runway

Stoke Therapeutics (STOK) presented at the Cantor Fitzgerald conference, highlighting progress in its Phase III EMPEROR trial for Dravet syndrome, which completed enrollment ahead of schedule with 162 patients. The company expects top-line data in Q3 2027 and plans a rolling NDA submission in H1 2027. Stoke reported $400M in pro forma cash as of June 30, 2024, providing a runway through early 2028. Open-label extension data show a 75% sustained seizure reduction over four years. The stock traded

investing.com3 min
SEP 9
$STOKMedAI 8/10

STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones

Stoke Therapeutics (STOK) announced key milestones, including a phase III readout for Dravet syndrome within 12 months and progress in ADOA trials. Zorevunersen showed sustained 75% seizure reduction and functional gains, with long-term efficacy supported by OLE data. The EMPEROR study is well-powered, and the company's commercial strategy leverages robust clinical evidence.

tradingview.com1 min
SEP 4
$STOKMedAI 8/10

Stoke and Biogen report long-term zorevunersen Dravet data

Stoke Therapeutics and Biogen reported long-term data for zorevunersen, an investigational Dravet syndrome therapy, showing sustained seizure reductions and cognitive improvements over four years. The Phase 3 EMPEROR trial has completed enrollment, with data expected in Q3 2027 ahead of a planned U.S. NDA submission.

grafa.com1 min
SEP 4
$BIIBMedAI 8/10

Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrom

Stoke Therapeutics and Biogen presented long-term data at the 16th European Epilepsy Congress, showing zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a and OLE studies demonstrated durable seizure reductions, cognitive and behavioral improvements, and quality of life enhancements. The Phase 3 EMPEROR study data is expected in Q3 2027, aiming to complete the U.S. NDA submission. Zorevunersen was generally well tolerated, with some patients treated for over 5 years. Dravet synd

finanznachrichten.de2 min